Future of Computational Toxicology: Broad Application into Human Disease and Therapeutics

Computational Toxicology: Risk Assessment for Pharmaceutical and Environmental Chemicals

Volumn , Issue , 2006, Pages 725-749

  Johnson, Dale E ^a   Rodgers, Amie D ^a   Sudarsanam, Sucha ^a  

^a Emiliem Inc   (United States)

Author keywords

Computational toxicologist toolbox; Computational toxicology applications; Gap analysis on current approaches

Indexed keywords

EID: 84889618833     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470145890.ch26     Document Type: Chapter

References (60)

1. Johnson DE, Rodgers AD. Computational toxicology: Heading toward more relevance in drug discovery and development. Curr Opin Drug Disc Devel 2006;9(1):29-37.
2. Greene N. Computer systems for the prediction of toxicity: An update. Adv Drug Deliv Rev 2002;54:417-31.
3. Matthews E, Contrera J. A new highly specific method for predicting the carcinogenic potential of pharmaceuticals in rodents using enhanced MCASE QSAR-ES software. Regul Toxicol Pharmacol 1998;28(3):242-2.
4. Snyder RD, Pearl GS, Mandakas G, Choy WN, Goodsaid F, Rosenblum IY. Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules. Environ Mol Mutagen 2004;43(3):143-58.
5. White AC, Mueller RA, Gallavan RH, Aaron S, Wilson AGE. A multiple in silico program approach for the prediction of mutagenicity from chemical structure. Mutat Res 2003;539:77-89.
6. Cariello NF, Wilson JD, Britt BH, Wedd DJ, Burlinson B, Gombar V. Comparison of the computer programs DEREK and TOPKAT to predict bacterial mutagenicity. Mutagenesis 2002;17(4):321-9.
7. Roche O, Trube G, Zuegge J, Pflimlin P, Alanine A, Schneider G. A virtual screening method for prediction of the hERG potassium channel liability of compound libraries. Chembiochem 2002;3:455-9.
8. Ekins S, Boulanger B, Swaan PW, Hupcey MA. Towards a new age of virtual ADME/TOX and multidimensional drug discovery. J Compuct Aided Drug Des 2002;16:381-401.
9. Johnson DE, Smith DA, Park BK. Linking toxicity and chemistry: Think globally, but act locally? Curr Opin Drug Disc Devel 2004;7(1):33-5.
10. Johnson D. The discovery-development interface has become the new interfacial phenomenon. Drug Discov Today 1999;4(12):535-6.
11. Johnson DE, Wolfgang GHI. Predicting human safety: screening and computational approaches. Drug Discov Today 2000;5(10):445-54.
12. Ekins S, Crumb WJ, Sarazan RD, Wikel JH, Wrighton SA. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. Pharmacol Exp Ther 2002;301:427-34.
13. Johnson DE, Smith DA, Park BK. Safety/toxicity threshold concepts in drug discovery and development. Curr Opin Drug Disc Devel 2005;8(1):24-6.
14. Paules R. Phenotypic anchoring: Linking cause and effect. Environ Health Perspect 2003;111:A338-9.
15. Stevens JL, Marnett LJ. Defining molecular toxicology: A perspective. Chem Res Toxicol 1999;12(9):747-8.
16. Marnett LJ. The future of toxicology. Chem Res Toxicol 2006;19(5):609.
17. Waters MD, Fostel JM. Toxicogenomics and systems toxicology: Aims and prospects. Nature Rev 2004;5:936-48.
18. Hieter P, Boguski M. Functional genomics: It's all how you read it. Science 1997;278:601-2.
19. Cunningham ML. Putting the fun into functional toxicogenomics. Tox Sci 2006; 92(2):347-8.
20. Yu X, Griffith WC, Hanspers K, Dillman JF, Ong H, Vredevoogd MA, Faustman EM. A system-based approach to interpret dose-and time-dependent microarray data: Quantitative integration of gene ontology analysis for risk assessment. Toxicol Sci 2006;92(2):560-77.
21. Rietjens IM, Alink GM. Future of toxicology: Low-dose toxicology and risk-benefit analysis. Chem Res Toxicol. 2006;19(8):977-81.
22. Ionannidis J. Materializing research promises: Opportunities, priorities and conflicts in translational medicine. J Tanslational Med 2004;2:5.
23. Pestka J, Zhou H-R. Toll-like receptor priming sensitizes macrophages to proin-flammatory cytokine gene induction by deoxynivalenol and other toxicants. Tox Sci 2006;92(2):445-55.
24. Machida K, Cheng KT, Sung VM, Levine AM, Foung, S and Lai MM: Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J Virol 2006;80(2):866-74.
25. Qi H-Y, Shelhamer JH. Toll-like receptor 4 signaling regulates cytosolic phospho-lipase A2 activation and lipid generation in lipopolysaccharide-stimulated macrophages. J Biol Chem 2005;280(47):38969-75.
26. Jaeschke H. Mechanisms of liver injury: II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. Am J Physiol Gastrointest Liver Physiol 2006;290:1083-88.
27. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-9.
28. Hoffman ES, Smith RET, Renaud RC. TLR-targeted therapeutics. Nature Rev Drug Discov 2005;4:879-80.
29. Luyendyk J, Lehman-McKeeman L, Nelson D, Bhaskaran V, Reilly T, Car B, Cantor G, Maddox J, Ganey P, Roth R. Unique gene expression and hepatocellular injury in the lipopolysaccharide-ranitidine drug Idiosyncrasy rat model: Comparison with famotidine. Toxicol Sci 2006;90:569-85.
30. Luyendyk J, Lehman-McKeeman L, Nelson D, Bhaskaran V, Reilly T, Car B, Cantor G, Deng X, Maddox J, Ganey P, Roth R. Coagulation dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine. J Pharmacol Exp Ther 2006;317:635-43.
31. Waring J, Liguori M, Luyendyk J, Maddox J, Ganey P, Stachlewitz R, North C, Blomme E, Roth R. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory che-mokines and neutrophils. JPET 2006;316:1080-7.
32. Pearson JM, Bailie MB, Fink GD, Roth RA. Neither platelet activating factor nor leukotrienes are ccritical mediators of liver injury after lipoolysaccharide administration. Toxicology 1997;121(5):181-9.
33. Wolfgang GH, McCabe RD, Johnson DE. Toxicity of subcutaneously administered recombinant human interleukin-2 in rats. Toxicol Sci 1998;42(1):57-63.
34. Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am J Physiol Gastrointest Liver Physiol 2003;284:G15-G26.
35. Tsung A, Hoffman RA, Izuishi K, Critchlow ND, Nakao A, Chan MH, Lotze MT, Geller DA, Billiar TR. Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol 2005;175(11):7661-8.
36. Smith MT. Mechanisms of Troglitizone Hepatotoxicity. Chem Res Toxicol 2003;16(16):679-87.
37. Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nature Rev Genet 2004;5:645-65.
38. Griffiths JD, Stark RJ, Ding JC, Cooper IA. Vincristine neurotoxicty in Charcot-Marie-tooth syndrome. Med J Aust 1985;143:305-6.
39. Park BK, Pirmohamed-M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective. Chem Res Toxicol 1998;11(9):969-88.
40. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, LaGrenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292(21):2585-90.
41. Bugrim A, Nikolskaya T, Nikolsky Y. Early prediction of drug metabolism and toxicity: Systems biology approach and modeling. Drug Discov Today 2004;9(3): 127-35.
42. Apic G, Ignjatovic T, Boyer S, Russell RB. Illuminating drug discovery with biological pathways. FEBS Lett 2005;579(8):1872-7.
43. Rajasethupathy P, Vayttaden SJ, Bhalla US. Systems modeling: A pathway to drug discovery. Curr Opin Chem Biol 2005;9:400-6.
44. Rishton G. Failure and success in modern drug discovery: guiding principles in the establishment of high probability of success drug discovery organizations. Med Chem 2005;1:519-27.
45. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb F, Rosenzweig A, Salomon R, Van Etten R, Alroy J, Durand JB, Force T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Med 2006;12(8):908-916.
46. Biomarkers Definitions Working Group, Bethesda, Md. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
47. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003;2(7):566-80.
48. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26.
49. Ekins S. Systems-ADME/Tox: Resources and network approaches. J Pharmacol Toxicol Meth 2006;53:38-66.
50. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. PNAS 2004;101(25):9309-14.
51. Mattingly CJ, Rosenstein MC, Davis AP, Colby GT, Forrest JN, Boyer JL. The comparative toxicogenomics database: A cross-species resource for building chem-ical-gene interaction networks. Toxicol Sci 2006;92(2):587-95.
52. Currie RA, Bombail V, Oliver JD, Moore DJ, Lim FL, Gwilliam V, Kimber I, Chipman K, Moggs JG, Orphanides G. Gene ontology mapping as an unbiased method for identifying molecular pathways and processes affected by toxicant exposure: Application to acute effects caused by the rodent non-genotoxic carcinogen diethylhexylphthalate. Toxicol Sci 2005;86(2):453-69.
53. Xirasagar S, Gustafson SF, Huang C, Pan Q, Fostel J, Boyer P, Merrick BA, Tomer KB, Chan DD, Yost KJ, Choi D, Xiao N, Stasiewicz S, Bushel P, Waters MD. Chemical effects in biological systems (CEBS) object model for toxicology data, SysTox-OM: Design and application. Bioinformatics 2006;22(7):874-82.
54. Mao X, Cai T, Olyarchuk JG, Wei L. Automated genome annotation and pathway identification using the KEGG orthology (KO) as a controlled vocabulary. Bioinformatics 2005;21(19):3787-93.
55. Hoffmann R, Valencia A. Life cycles of successful genes. Trends Genet 2003; 19(2):79-81.
56. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, Mindrinos MN, Davis RW, Tompkins RG, Lowry SF. A network-based analysis of systemic inflammation in humans. Nature 2005;437(7061):1032-7.
57. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 2005;65(19):8679-89.
58. Remm M, Storm CEV, Sonnhammer ELL. Automatic clustering of orthologs and in-paralogs from pairwise species comparisons. J Mol Biol 2001;314(5):1041-52.
59. Kim DH, Ausubel FM. Evolutionary perspectives on innate immunity from the study of Caenorhabditis elegans. Curr Opin Immunol 2005;17(1):4-10.
60. Kelley BP, Sharan R, Karp RM, Sittler T, Root DE, Stockwell BR, Ideker T. Conserved pathways within bacteria and yeast as revealed by global protein network alignment. PNAS 2003;100(20):11394-99.